This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Influence of Probiotics on Infections in Cirrhosis (PIC)

This study has been completed.
Sponsor:
Collaborator:
Austrian Science Fund (FWF)
Information provided by (Responsible Party):
Medical University of Graz
ClinicalTrials.gov Identifier:
NCT01607528
First received: April 13, 2012
Last updated: May 4, 2016
Last verified: May 2016
  Purpose

Liver cirrhosis is the 10th most common cause of death in the western world. Infection is the most common precipitant of deterioration of liver function in cirrhosis. Endotoxin, derived from gram-negative organisms in the gut, can enter the circulation due to increased gut permeability and contributes to neutrophil dysfunction, infection risk and mortality in alcoholic cirrhotics. As probiotics decrease gram-negative organisms in the gut and/or decrease gut permeability, the investigators hypothesize that probiotic treatment would restore neutrophil function and prevent infection in alcoholic cirrhosis.

The investigators hypothesize that administration of a probiotic mixture in patients with liver cirrhosis will improve innate immune function through alteration of the gut bacterial flora and gut barrier integrity.

The aim of this randomised, double-blinded placebo-controlled study is to assess whether food supplementation with probiotic mixture improves neutrophil phagocytic capacity in patients with cirrhosis and decreases the incidence of significant infections.

92 patients with alcoholic cirrhosis will be included according to a sample size calculation from preliminary data. Patients will be randomized in two groups: Group 1 receives a probiotic mixture Group 2 receives a similar looking and tasting placebo without bacteria. The recruited patients will be treated for 6 months. Besides routine clinical and laboratory assessments, neutrophil function, toll-like receptor expression, endotoxin levels, bacterial DNA, cytokine levels, albumin oxidation, gut permeability and analysis of gut microflora will be performed. Furthermore nutritional status and quality of life will be assessed.

Primary endpoints will be neutrophil phagocytosis. Secondary endpoints will be significant infection, neutrophil oxidative burst, neutrophil toll-like receptor expression, endotoxin levels, bacterial DNA; cytokine levels, albumin oxidation, gut barrier function and bacterial flora, nutritional status and quality of life.

If our hypothesis holds true, probiotics will provide an easily applicable and cost effective method to improve immune function and to prevent infection in liver cirrhosis. It is possible that this can improve survival of patients with liver cirrhosis.


Condition Intervention
Liver Cirrhosis Dietary Supplement: Winclove-849 Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Probiotic Modulation of Gut Microflora in Cirrhosis: Influence on Immune Function and Infections

Resource links provided by NLM:


Further study details as provided by Medical University of Graz:

Primary Outcome Measures:
  • Change in neutrophil phagocytic capacity [ Time Frame: Change from baseline to 6 months ]
    Percentage of neutrophil granulocytes showing phagocytosis of FITC (fluorescein isothiocyanate) -labelled E.coli bacteria


Secondary Outcome Measures:
  • Number of clinically significant infections [ Time Frame: during 12 months ]
    Occurence of infections that require specific treatment and/or hospitalisation during the study period of 12 months

  • endotoxin levels [ Time Frame: 0, 6, 12 months ]
    Endotoxin in serum (EU/ml)

  • neutrophil oxidative burst [ Time Frame: 0, 6, 12 months ]
    percentage of neutrophil granulocytes showing oxidative burst with and without stimulation and mean fluorescence activity

  • neutrophil toll like receptor expression [ Time Frame: 0, 6, 12 months ]
    percentage of neutrophil granulocytes showing TLR (Toll-like receptor) 2, TLR4 or TLR9 expression and mean fluorescence activity

  • albumin oxidation [ Time Frame: 0, 6, 12 months ]
    oxidative status of albumin in the plasma (percentage of (human mercaptalbumin) HMA, (human non-mercaptalbumin) HNA1 and HNA2)

  • inflammatory response [ Time Frame: 0, 6, 12 months ]
    elevation of one or more inflammatory markers: C reactive protein (mg/ml), lipopolysaccharide binding protein (ng/ml), soluble CD (cluster of differentiation) 14 (ng/ml)

  • bacterial flora [ Time Frame: 0, 6, 12 months ]
    isolation of bacterial DNA and sequencing the gut microbiome from stool and duodenal aspirate

  • quality of life [ Time Frame: 0, 6, 12 months ]
    (short form) SF-36 questionaire

  • nutritional status [ Time Frame: 0,6, 12 months ]
    subjective global assessment

  • changes in gut permeability over time [ Time Frame: 0, 6, 12 months ]
    elevated lactulose mannitol ratio, elevated zonulin


Enrollment: 92
Study Start Date: July 2012
Study Completion Date: September 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Probiotic
6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 10E9 cfu/g per day
Dietary Supplement: Winclove-849
6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
Placebo Comparator: Placebo
A similar looking and tasting powder
Dietary Supplement: Placebo
A similar looking and tasting powder with no active substances

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria: • Patients aged between 18-80 years

  • Clinical and radiological evidence of cirrhosis, and/or biopsy proven liver cirrhosis of any cause
  • Informed consent

Exclusion Criteria:

  • Child-Pugh score > 11
  • Abstinence from alcohol for < 2 weeks at the time of screening for inclusion
  • Clinical evidence of active infection
  • Antibiotic treatment within 7 days prior to enrolment
  • Gastrointestinal haemorrhage within previous 2 weeks
  • Use of immunomodulating agents within previous month (steroids etc.)
  • Use of proton pump inhibitors for preceding two weeks
  • Concomitant use of supplements (pre-, pro-, or synbiotics) likely to influence the study
  • Renal failure (such as hepatorenal syndrome), creatinine >1.7 mg/dL
  • Hepatic encephalopathy II to IV
  • Pancreatitis
  • Other organ failure
  • Hepatic or extra-hepatic malignancy
  • Pregnancy
  • Presumed non-compliance to the study medication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01607528

Locations
Austria
Department of Internal Medicine, Medical University of Geraz
Graz, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
Austrian Science Fund (FWF)
Investigators
Principal Investigator: Vanessa Stadlbauer-Köllner, MD Medical University of Graz
  More Information

Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT01607528     History of Changes
Other Study ID Numbers: PIC-2010
Study First Received: April 13, 2012
Last Updated: May 4, 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Fibrosis
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on July 21, 2017